To back the launch of its new integrated chiral chemistry offer,
global lab chemical and life sciences company
) custom manufacturing and services division "SAFC" is integrating
its chiral chromatography screening and small scale purification
operations and moving them to its Cambridge, UK, facility.
Chromatography is a technique for separating mixtures.
Sigma-Aldrich noted that analytical equipment has been deployed
at the Pharmorphix solid state research laboratories in Cambridge.
They have been moved from the company's Supelco Analytical
subsidiary in Bellefonte, Pennsylvania, where the chiral screening
services were carried out earlier. The Pharmorphix laboratories are
expected to come on line in July 2012.
SAFC's chiral offernings include separations by Chiral Gas
Chromatography (GC) and Liquid Chromatography (LC),
commercial-scale Simulated Moving Bed (SMB) chromatography and
large scale crystallization. Separation by chromatography is an
essential step in the synthesis of chiral molecules.
The company's Cambridge facility will emerge as the global base
for SAFC's chiral offerings. The unification of SAFC's operations
will offer customers a single, dedicated point of contact from
early-stage research and development phases through final
production. The unit's chiral chromatography method development
squad will be headed by Paul Rodwell, an ex-Senior Principal
Sigma-Aldrich, which had annual revenues of $2.5 billion in
2011, makes and distributes various biochemicals and organic
chemicals that are used in scientific and genomic research,
biotechnology, pharmaceutical development, diagnosis of diseases
and chemical manufacturing. It is a leader in chiral offerings used
in chemical synthesis, drug discovery and analytical
SAFC is focused on biochemical production and manufacturing of
complex organic compounds. Sales from the unit climbed 9% in the
most recent quarter. However, organically, SAFC revenues rose just
1%, partly impacted by weakness in the LED markets.
Sigma-Aldrich's significant investments in sales, marketing and
R&D initiatives are generating demand for its products. To
boost growth, the company plans to increase its focus on marketing,
business development and R&D, while continuing with its efforts
to improve process and operations management. Moreover, Sigma
Aldrich is seeking to take advantage of country-specific
opportunities by expanding its presence in high-growth emerging
However, the company's Research Business would continue to face
economic challenges due to uncertainties in the U.S. and Europe.
Its research sales would languish because of funding uncertainties
in the U.S. owing to budget constraints.
Our long-term Neutral recommendation on the stock is in
agreement with a short-term Zacks #3 Rank (Hold).
PFIZER INC (PFE): Free Stock Analysis Report
SIGMA ALDRICH (SIAL): Free Stock Analysis
To read this article on Zacks.com click here.